Skip to main content
Fig. 1 | Cancer Cell International

Fig. 1

From: TMEFF2 promoter hypermethylation is an unfavorable prognostic marker in gliomas

Fig. 1

TMEFF2 expression and methylation in glioma tissues and glioblastoma cells. a Representative images of TMEFF2 immunohistochemical staining of paired tumor/peritumor tissues from one glioma patient and tissue from one epilepsy patient. b Boxplot of the TMEFF2 immunohistochemistry staining score in tumor and peritumor tissues (n = 75). c Bar gragh of the RT-PCR of TMEFF2 expression in paired tumor/peritumor glioma patient tissues (n = 23). Error bars represent the SD of tissues. d Boxplot of the total methylation levels of BSAS in GBM cells and SVG p12 cells. e Boxplot of the total methylation levels of BSAS in each GBM cell and SVG p12 cell sample. f Line plot of CpG sites of the fourth CpG island of the TMEFF2 promoter in GBM cells and SVG p12 cells. g Methylation plot of the fourth CpG island of the TMEFF2 promoter in GBM cells and SVG p12 cells. CpG sites are presented at each point on each line. **P < 0.01, and ***P < 0.001

Back to article page